Catalyst Pharmaceuticals (NASDAQ:CPRX) Research Coverage Started at Robert W. Baird

Robert W. Baird assumed coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report released on Tuesday morning, Marketbeat.com reports. The firm issued an outperform rating and a $28.00 price objective on the biopharmaceutical company’s stock.

CPRX has been the topic of several other reports. Bank of America reissued a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. HC Wainwright increased their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Truist Financial boosted their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Stephens assumed coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 target price for the company. Finally, StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $32.25.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $23.06 on Tuesday. The firm has a fifty day moving average price of $22.07 and a 200 day moving average price of $20.87. Catalyst Pharmaceuticals has a 1 year low of $13.12 and a 1 year high of $24.64. The stock has a market cap of $2.75 billion, a P/E ratio of 19.54, a P/E/G ratio of 2.25 and a beta of 0.80.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 79,500 shares of company stock worth $1,754,140. Corporate insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth about $27,000. GAMMA Investing LLC increased its holdings in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 681 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $50,000. Larson Financial Group LLC lifted its holdings in Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in Catalyst Pharmaceuticals in the fourth quarter worth approximately $65,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.